|
gptkbp:instanceOf
|
gptkb:receptor_tyrosine_kinase
gptkb:drug
|
|
gptkbp:administeredBy
|
oral
|
|
gptkbp:approvedBy
|
gptkb:FDA
2004
|
|
gptkbp:ATCCode
|
L01EB02
|
|
gptkbp:bioavailability
|
60%
|
|
gptkbp:brand
|
gptkb:Tarceva
|
|
gptkbp:CASNumber
|
183321-74-6
|
|
gptkbp:contraindication
|
pregnancy
|
|
gptkbp:developedBy
|
gptkb:Genentech
gptkb:Roche
gptkb:OSI_Pharmaceuticals
|
|
gptkbp:eliminationHalfLife
|
36 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C22H23N3O4
|
|
gptkbp:KEGGID
|
D04001
|
|
gptkbp:legalStatus
|
expired
prescription only
|
|
gptkbp:mechanismOfAction
|
EGFR tyrosine kinase inhibition
|
|
gptkbp:metabolism
|
gptkb:CYP1A2
gptkb:CYP3A4
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:proteinBinding
|
93%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL521
176870
DB00530
154749
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
diarrhea
anorexia
fatigue
rash
|
|
gptkbp:synonym
|
gptkb:OSI-774
|
|
gptkbp:target
|
gptkb:EGFR
|
|
gptkbp:UNII
|
N2Z4N4FO8O
|
|
gptkbp:usedFor
|
gptkb:non-small_cell_lung_cancer
pancreatic cancer
|
|
gptkbp:bfsParent
|
gptkb:Non-Small_Cell_Lung_Cancer
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Erlotinib
|